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Abstract
 
The number of circulating follicular B lymphocytes is normally kept within a precise range de-
spite their dispersion through the body and daily overproduction of precursors in the bone
marrow. By establishing a genome wide recessive mutation screen in C57BL/6 mice to iden-
tify critical components of immune system regulation, we identified a mutant strain with selec-
tive deficiency in recirculating B cells but not immature or peritoneal B1 cells. Analysis of
mixed bone marrow chimeras established that the mutation affects a cell autonomous process
within B cells that is required for their accumulation after emigrating to peripheral lymphoid
organs. The defect is caused by a point mutation in the gene encoding transcription factor nu-
clear factor (NF)-
 
 
 
B2, terminating the encoded protein within the DNA-binding domain.
These findings establish the feasibility of analyzing immune regulation by genome wide mutant
screens and demonstrates an intrinsic requirement for NF-
 
 
 
B2 in regulating circulating follicu-
lar B cell numbers.
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Introduction
 
Abnormal numbers of circulating lymphocytes are associ-
ated with leukemia/lymphoma, immunodeficiency, and au-
toimmunity. Despite the importance of processes that regu-
late peripheral lymphocyte numbers, details on the genetics
and pathways involved remain to be elucidated. To investi-
gate the components of pathways involved in immune sys-
tem regulation we have explored the possibility of using the
potent germline mutagen ethylnitrosourea (ENU) to gener-
ate libraries of C57BL/6 mice with random point mutations
throughout their genomes. ENU was originally defined as a
supermutagen for mouse spermatogonial stem cells, by
treating outbred male mice and then breeding with tester
females homozygous for seven visible recessive traits (1).
This one generation “specific locus test” revealed new re-
cessive loss-of-function alleles induced by ENU on average
once in every 700 gametes. Several potential barriers may
nevertheless block extension of this strategy to the entire ge-
nome, to discover recessive mutations affecting the immune
system of adult mice in an unbiased manner. First, when in-
breeding strategies are used to bring recessive ENU traits to
homozygosity across an entire mutagenized genome, the
frequency of embryonic or neonatal lethal mutations may
prevent sufficient animals reaching adulthood. Second, the
burden of homozygozed mutations may result in complex,
multigenic interactions so that the majority of immunologi-
cal traits may fail to breed true and be difficult to pinpoint.
 
Third, genome wide screens impose the difficulty of mapping
each mutation to a chromosomal interval and identifying
the mutated gene. On the other hand, it would be useful if
new immunological mutants were induced in the C57BL/6
strain, since a large number of congenic and mutant strains
are available for immunobiological analyses in this strain
background. Here, we demonstrate the feasibility and utility
of genome wide mutagenesis and screening for recessive
immunological traits. By isolating and analyzing a mutant
strain with diminished numbers of circulating B cells, we
confirm earlier studies on nuclear factor (NF)-
 
 
 
B2–defi-
cient mice (2–4) and extend these findings to show that the
transcription factor NF-
 
 
 
B2 plays an essential, B cell–intrin-
sic role in maintaining the numbers of mature B2 and mar-
ginal zone (MZ) B cells, while B1 cell numbers do not re-
quire this factor.
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tralian National University, Canberra ACT 2601, Australia. Phone: 61-2-
6125-3621; Fax: 61-2-6125-8512; E-mail: Chris.Goodnow@anu.edu.au 
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Materials and Methods
 
ENU Mutagenesis.
 
Male C57BL/6 mice 8–15 wk old were
treated three or four times, 1 wk apart, with 85 mg/kg or 100
mg/kg 
 
N
 
-ethyl-
 
N
 
-nitrosourea (Sigma-Aldrich) freshly dissolved
in 10% ethanol in citrate buffer, pH 5.0, as described previously
(1). The xander strain arose from a G0 treated with the dose of
4 
 
 
 
 85 mg/kg ENU.
 
Flow Cytometry.
 
Single cell suspensions were stained with
FITC-conjugated anti-IgM, anti-B220, and anti-Ly5a and PE-
conjugated anti-Thy1.2, anti-IgD, anti-CD23, and anti-B220
(BD PharMingen). Biotinylated anti-CD21 and anti-Ly5a were
secondary stained with streptavidin cychrome (BD PharMingen).
Samples were collected on a FACScan™ (Becton Dickinson) and
data was analyzed using Flowjo™ software (Tree Star).
 
Immunohistochemistry.
 
5-
 
 
 
m sections of frozen spleen were
cut and fixed in cold acetone, air-dried, and stored at –20
 
 
 
C.
Sections were immunostained with mAbs anti-IgM (Serotec and
The Binding Site), anti-CD3 (Serotec), anti-IgD (Southern
Biotechnology, Inc.), anti-CD21 (BD PharMingen), and
MOMA1 (Serotec). HRP-conjugated antibodies were devel-
oped with 3,3
 
 
 
-diaminobenzidine tablets (Sigma-Aldrich). Bio-
tinylated antibodies were stained with streptavidin alkaline
phosphatase and visualized using alkaline phosphatase substrate
kit (Vector Laboratories).
 
Bone Marrow Chimeras.
 
Recipient mice were irradiated with
two doses of 5.5 Gy 3 h apart. The next day, recipient mice were
injected intravenously with a total of 2 
 
 
 
 10
 
6
 
 bone marrow (BM)
cells. Mice were killed and analyzed 8 wk after reconstitution.
 
Mapping.
 
The 
 
xdr
 
 mutation was out crossed to the NOD.
H-2
 
k
 
 strain by breeding male 
 
xdr/xdr
 
 mice on C57BL/6 back-
ground to NOD.H-2
 
k
 
 females to yield F1 intercross mice. F1 mice
were intercrossed to generate F2 intercross mice that were
screened to identify mutant individuals. Analysis of F2 intercross
DNA was performed by amplifying regions of the genome with
defined simple sequence length polymorphism (SSLP) markers
(5). C57BL/6 and NOD.H-2
 
k
 
 DNA amplification products from
each SSLP were resolved by agarose gel electrophoresis.
 
Sequencing and Protein Expression.
 
Spleen cDNA was ampli-
fied by PCR and sequenced using 16–20 bp NF-
 
 
 
B2 comple-
mentary primers (sequences available on request). Cell lysates
were prepared in RIPA buffer from splenocytes and fraction-
ated by SDS-PAGE using standard protocols. Membranes were
probed with a rabbit polyclonal antibody against NF-
 
 
 
B2
(Santa Cruz Biotechnology, Inc.), followed by HRP-conju-
gated goat anti–rabbit IgG (Santa Cruz Biotechnology, Inc.)
 
and developed with enhanced chemiluminescence (NEN Life
Sciences).
 
Results
 
Generation of ENU Mutant Strain ‘xander’.
 
We gener-
ated a library of recessive mutant mice by treating male
C57BL/6 mice with ENU. To observe the effect of reces-
sive mutations, which are the most frequent class of loss-of-
function mutation, we adopted a strategy of inbreeding
mice to homozygozity by constructing three generation
pedigrees (Fig. 1 A). ENU treated male mice (generation 0;
G0) were mated with wild-type (WT) C57BL/6 females
yielding G1 offspring. Each G1 mouse is heterozygous for a
different constellation of point mutations inherited on the
paternal chromosomes. To homozygoze these mutations, a
pedigree is founded by a single G1 male mated with a WT
C57BL/6 female and then with 4–6 of his G2 daughters to
yield G3 mice. Since half of the G2 daughters will inherit
any particular mutation carried by the G1, one in eight of
the G3 mice are expected to be homozygous for this muta-
tion. A target of 24 G3 mice was bred in each pedigree and
reared to adulthood, and their blood lymphocyte subsets
screened by flow cytometry. In pedigree number 3, several
G3 mice were identified with fewer circulating B cells in
the blood (Fig. 1 B). The B cell deficiency was inherited as
a simple recessive Mendelian trait both during intercrossing
with siblings on the C57BL/6 background and in an out-
cross with NOD.H-2
 
k
 
 followed by an F2 intercross. The
mutant strain thus established was named ‘xander’ (
 
xdr
 
).
 
xdr/xdr Mice Have a Selective Deficiency in the Mature B2
Cell Population.
 
Analysis of splenic lymphocyte popula-
tions in 
 
xdr/xdr
 
 mice reveals a reduction in the number of B
cells, but not T cells compared with WT mice (Fig. 2 A).
After B cell formation in the BM, B cell maturation in the
spleen proceeds from transitional type 1 (T1) cells that have
recently emigrated from the BM to transitional type 2 (T2)
cells, mature recirculating (follicular) B cells and MZ B cells.
These subsets can be distinguished by cell surface expression
of IgM, IgD, and CD21 (6). Analysis of B cell subsets in the
Figure 1. An ENU-induced recessive mutation causing selective deficiency of peripheral B cells. (A) Initial generations of ‘xander’ pedigree. Note that
apparent fluctuations from expected Mendelian frequency in the small numbers shown are not significant, and that the expected frequencies were ob-
served in large crosses. Black squares and circles, affected individuals; white squares and circles, unaffected; cross, not typed by blood. (B) Reduced num-
bers of B cells in blood of xdr/xdr mice compared with heterozygous and WT siblings. Representative FACS® plots of B220 and Thy1.2 expression on
blood from C57BL/6 and xdr/xdr mice, and the percent of each cell subset within the lymphocyte gate. Graph shows the percentage of B220  and
Thy1.2  cells for xdr/xdr, xdr/  and WT siblings. 
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spleens shows that 
 
xdr/xdr
 
 mice have significantly reduced
numbers of T2, mature, and MZ B cells compared with
WT mice (Fig. 2 B). Recirculating B cells were also dramat-
ically reduced in blood (Fig. 1) and all peripheral lymph
nodes (unpublished data). There was no significant reduc-
tion in numbers of T1 B cells, suggesting that B cell export
from the BM was normal. Consistent with normal BM B
cell production, there was no difference in the percent of
pro-B/pre-B cells or immature B cells in the BM of WT
and 
 
xdr/xdr
 
 mice, but recirculating mature B cells were
again reduced (Fig. 2 C). These results are consistent with a
defect in the accumulation of mature B cells in 
 
xdr/xdr
 
 mice.
The B1 subset of mature peripheral B cells differs from
recirculating B2 cells in its anatomical localization, re-
stricted Ig repertoire, cell surface markers, and capacity for
self-renewal (7). B1 cells were enumerated in the perito-
neal cavity of 
 
xdr/xdr
 
 and WT mice. In contrast to the de-
ficiency of mature B cells in other lymphoid compart-
ments, 
 
xdr/xdr
 
 mice had a sevenfold increase in the number
of B1 cells in the peritoneal cavity (Fig. 2 D). Interestingly,
the number of B2 cells in the peritoneal cavity is compara-
ble for WT and 
 
xdr/xdr
 
 mice (Fig. 2 D).
 
xdr/xdr Mice Have Abnormalities in Secondary Lymphoid
Tissues.
 
In addition to the deficiency in recirculating B
cells, 
 
xdr/xdr
 
 mice have abnormalities in secondary lym-
Figure 2. Decreased numbers of mature B2 cells in spleen, but normal B cell production in BM. (A) Peripheral B cell deficiency, but normal T cell
numbers in xdr/xdr mice. Graphs show the mean number of cells   SD (n   3). Gray bars, C57BL/6; white bars, xdr/xdr. (B) Splenic B cell subsets. T2
cells are IgMhigh IgD  and mature B cells are IgMlow and IgD . Histograms of CD21 expression, after gating on IgMhigh IgD  cells, resolves T1 cells
(CD21 ) from MZ B cells (CD21high). Significant differences as determined by Student’s t test are represented as *P   0.05, **P   0.01, and ***P  
0.001. Results shown are representative of several independent experiments. (C) BM pro- and pre-B cells (B220low IgM ), immature B cells (B220low
IgM  IgD ), and recirculating mature B cells (B220high IgM  IgD ). (D) Numbers of peritoneal B1 cells (IgM  CD23 ) and B2 cells (IgM  CD23 ).
Equivalent results were obtained using B220 and CD5 to resolve these subsets.
 
Figure 3.
 
Abnormal splenic microarchitecture in 
 
xdr/xdr
 
 mice. Spleen
sections from WT and 
 
xdr/xdr
 
 mice were immunostained for expression
of (A) IgM (brown) and CD3 (blue), (B) IgD (brown) and IgM (blue),
(C) IgM (brown) and MOMA1 (blue) and (D) CD21. T,
 
 
 
T cell zone; B,
B cell follicle; R, red pulp; MMM, marginal metallophilic macrophages. 
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phoid tissues including small peripheral lymph nodes and
disturbed splenic microarchitecture. In spleen sections from
 
xdr/xdr
 
 mice, the T cell zone is normal in appearance, but
B cell follicles are reduced to a small ring around the T
zone and MZ B cells are visible although fewer in number
(Fig. 3, A and B). Marginal metallophilic macrophages
(MMM) detected with MOMA-1 staining form a continu-
ous ring around the white pulp in spleens of WT animals
whereas there are few MOMA1
 
 
 
 cells in 
 
xdr/xdr
 
 spleens
(Fig. 3 C). Follicular dendritic cells (FDC) detected by high
expression of CD21 form prominent networks within the
B cell follicles in WT spleen sections, whereas these FDC
clusters are not visible in spleen sections from 
 
xdr/xdr
 
 mice
(Fig. 3 D).
 
B Cell Deficiency in xdr/xdr Mice Is Due to a B Cell Intrinsic
Defect.
 
To determine if the circulating B cell deficiency
was secondary to these FDC and macrophage supporting
cell abnormalities or due to a B cell intrinsic defect, BM
chimeras were constructed with mixtures of normal and
mutant BM that could be distinguished by alleles of the cell
surface marker Ly5/CD45 (Fig. 4). In the test group (
 
xdr
 
versus WT chimeras), irradiated B6.Ly5
 
a
 
 recipient mice
were reconstituted with a mixture containing equal num-
bers of 
 
xdr/xdr
 
 B6.Ly5
 
b
 
 and WT B6.Ly5
 
a
 
 BM cells. As
controls, B6.Ly5
 
a
 
 recipients received equal numbers of
B6.Ly5
 
b
 
 and B6.Ly5
 
a
 
 BM cells (WT versus WT chimeras).
After reconstitution, the control (WT versus WT) chimeric
animals contained equivalent proportions of Ly5
 
a
 
 and Ly5
 
b
 
pre-B cells, immature, and mature B cells in their BM and
periphery, indicating equal reconstitution with the two
sources of stem cells and equal accumulation of mature B
cell progeny (Fig. 4). The 
 
xdr
 
 versus WT chimeras were
 
also equally reconstituted with the two donor marrows,
and formed similar numbers of mutant and WT pre-B cells
and immature B cells in their BM (Fig. 4). The numbers of
IgM
 
 
 
IgD
 
  
 
splenic cells, containing the recent BM emi-
grants, was also not significantly different, but there was a
dramatic and selective deficiency of more mature B cells of
 
xdr/xdr
 
 origin such that only a few percent of mature B
cells in 
 
xdr
 
 versus WT recipients were of 
 
xdr/xdr
 
 origin and
there were almost no 
 
xdr/xdr
 
-derived MZ B cells (Fig. 4).
Since WT B cells accumulated normally in the 
 
xdr
 
 versus
WT chimeras, the selective deficit in mutant B cell accu-
mulation establishes that the mutation disrupts a cell auton-
omous step within B cells rather than any defect in other
supporting hemopoietic cells.
 
xdr/xdr Mice Have a Point Mutation in Gene Encoding
Transcription Factor NF-
 
 
 
B2.
 
An F2 intercross between
B6 
 
xdr/xdr
 
 and NOD.H-2
 
k
 
 mice was used to locate the
mutated gene (Fig. 1 A). From 9 pairs of F2 breeders, 108
offspring were typed for blood B cell deficiency. 32 off-
spring were affected (30%) confirming a simple, fully pene-
trant recessive trait. Pooled DNA from affected individuals
was typed using a genome wide panel of SSLP markers (5),
revealing linkage to chromosome 19. Typing individual
animals with additional SSLP markers localized the gene
between D19Mit53 and D19Mit70 (Fig. 5 A). The Nf- b2
gene within this interval was a strong candidate because
like xdr/xdr mice, Nf- b2 knockout animals exhibit B cell
defects and lack FDC networks and MOMA1  MZ mac-
rophages in the spleen (2–4).
NF- B2 mRNA was amplified by RT-PCR from the
spleens of WT and xdr/xdr mice. Amplification of exons 5–8
yielded multiple aberrant sized products from xdr/xdr mice,
Figure 4. Intrinsic defect in peripheral B cells in xdr/xdr mice. Lethally irradiated B6.Ly5a recipient mice were reconstituted with a mixture of 106
B6.Ly5b and 106 B6.Ly5a marrow (WT versus WT) or 106 B6.Ly5b xdr/xdr and 106 B6.Ly5a marrow (xdr versus WT). Chimeric mice were killed 8 wk
after reconstitution and B cell subsets derived from the two donors were distinguished by staining for cell surface marker Ly5a. There was no significant
difference in the absolute number of spleen cells: 6.68   107   2.76   107 for WT versus WT; 5.89   107   1.4   107. Graphs show the mean   SD
(n   4). Gray bars, Ly5a; white bars, Ly5b. Significant differences as determined by Student’s t test are represented as **P   0.01 and ***P   0.001. Data
is representative of several experiments.1117 Miosge et al. Brief Definitive Report
none of which correspond to the WT species (Fig. 5 B).
cDNA from the amplification of exons 5–8 was cloned and
sequenced (Fig. 5 C). In xdr/xdr mice no correctly spliced
products were found and five different aberrant transcript
types were revealed. Two classes retained an unspliced in-
tron between exon 6 and 7. In the others, exon 6 was
spliced to cryptic splice acceptor sites within exon 7 resulting
in the absence of the first 34 or 37 bases of exon 7. All of the
aberrant products generate in frame-stop codons that would
prematurely truncate NF- B2 in the middle of the DNA-
binding domain (8) so that no functional protein could be
made. The absence of full-length NF- B2 protein in xdr/xdr
mice was confirmed by Western blot analysis (Fig. 5 D).
Sequencing of genomic DNA revealed the ENU-
induced point mutation in Nf- b2 as an intronic T to A
conversion of base 3163 between the parental B6 and xdr
mutant, in the conserved polypyrimidine tract of the exon 7
splice acceptor site (Fig. 5 E; reference 8). This base
change, thus prevents mRNA splicing of exon 6 to the
correct exon 7 acceptor site, causing an accumulation of
unspliced intermediates and aberrant splicing to sequences
within exon 7 that resemble splice acceptor sites. The effect
of the ENU-induced point mutation on mRNA splicing
and protein expression is shown schematically in Fig. 5 F.
Discussion
This study establishes the feasibility and utility of analyz-
ing immune regulation by genome wide screens for reces-
sive immune abnormalities induced in C57BL/6 mice by
Figure 5. Intronic point mutation in NF- B2 results in aberrant mRNA splicing and premature stop codons. (A) Chromosomal mapping of xdr/xdr
mutation. Haplotypes of individual xdr/xdr affected mice are shown. Black squares indicate C57BL/6 homozygote; white squares indicate C57BL/6/NOD
heterozygote. (B) Amplification of NF- B2 cDNA reveals multiple aberrant spliced products between exons 5–8 in xdr/xdr mice. Spleen cDNA from
WT and xdr/xdr mice was amplified by PCR using the indicated primer pairs. Primer pair 204F and 550R amplifies exons 2–5, 457F and 872R amplifies
exons 5–8 and 791F and 3013R amplify exons 8–23. (C) The PCR products resulting from amplification of exons 5–8 from WT and xdr/xdr mice were
cloned and sequenced. Intronic base number 3163 mutated in xdr/xdr mice shown as bold A. (D) Absence of NF B2 protein in xdr/xdr mice. Cell lysates
were prepared from the spleens of WT and xdr/xdr mice and probed with a polyclonal antibody against NF- B2. (E) T to A conversion of Nf- b2 in-
tronic base 3163 in amplified genomic DNA in xdr/xdr mice. (F) Schematic representation of the effect of the ENU-induced point mutation in Nf- b2.1118 Intrinsic Role for NF- B2 in Mature B2 Cells
ENU, and further defines the role of NF- B2 in regulating
B cell numbers. The mutation identified, in the gene en-
coding the transcription factor NF- B2, lies in an intron
and causes aberrant mRNA splicing so that the protein
reading frame is shifted and the protein coding region ter-
minated prematurely within the DNA-binding domain.
Thus, no functional NF- B2 protein is predicted, consis-
tent with the absence of p100 in Western blot analysis. The
aberrant splicing resulting from a point mutation is consis-
tent with previous analyses of ENU-induced mutations,
where  25% result from aberrant mRNA splicing (9).
Previous analyses of mice with a targeted null mutation
in NF- B2 found reduced numbers of B cells in the spleen
and absence of FDCs and MMM paralleling the findings
here (2–4). Our analysis extends these findings by showing
that the B cell deficiency first appears after the T1 stage of
B cell maturation in the spleen, severely reducing the folli-
cular and MZ populations in the spleen, lymph node, and
blood. The mixed chimera analysis establishes that the fail-
ure to accumulate these mature B cell subsets reflects a pri-
mary, cell intrinsic function of NF- B2 in these B cells or
their immediate T1/T2 precursors, rather than being sec-
ondary to NF- B2 defects in other hemopoietic or stromal
cells. We also show for the first time that NF- B2 is not
required to establish normal numbers of B2 and B1 cells in
the peritoneum, indeed the numbers of B1 cells are mark-
edly increased in the xander mice. Alymphoplasia (aly)
mice, a strain with a point mutation in NF- B-inducing
kinase (NIK), exhibit multiple defects including reduced
numbers of mature B cells in their peripheral lymphoid or-
gans (10). Interestingly, like xdr/xdr mice, aly/aly mice
have normal numbers of B2 cells and increased B1 cells in
the peritoneal cavity possibly arising from a migration de-
fect in aly/aly peritoneal B cells (10). The possible role of
NF- B2 downstream of NIK and chemokine receptor sig-
naling is yet to be explored.
The specific pattern of B cell subsets deficient in the
xander mutant mice raises the question of what B cell sur-
vival signaling pathway this transcription factor is likely to
serve as an essential intermediate. Two cell surface receptor
systems have recently emerged as regulating peripheral B
cell numbers. Mature B cells require a basal stimulation
through the B cell receptor (BCR) to survive and accumu-
late (11, 12). Unlike the selective deficiency of recirculat-
ing and MZ B cells in Nf- b2xdr mice, however, peripheral
B cell deficiencies due to defects in the BCR signaling
pathway are most marked within the peritoneal B1 subsets
(13–19). By contrast, the selective deficiency of splenic T2,
recirculating and MZ cells but not peritoneal B cells in Nf-
 b2xdr mice closely resembles the B cell phenotype of
A/WySnJ mice, in which the BAFF-R is naturally mutated
(20–22), and in mice deficient for BAFF (23, 24), or NIK
(10, 25). Thus it is reasonable to consider that NF- B2
plays a major role in B2 cells transducing the survival sig-
nals from BAFF/BAFF-R.
The demonstration here that NF- B2 is required within
follicular B cells for their accumulation, at precisely the de-
velopmental stages and locations that BAFF is required, is
interesting given that activating mutations in this transcrip-
tion factor or its partner, Bcl-3, occur in B cell lymphoma
(for a review, see reference 26). This signaling system may
normally regulate B cell numbers by requiring that circulat-
ing B cells regularly pass through limiting sites of BAFF
production such as the macrophage-rich zones of spleen
and lymph nodes (27). Mutations that activate this pathway
may thus allow follicular lymphoma cells to survive and ac-
cumulate independently of this trophic support. It will be
important in future work to better define the follicular B
cell intrinsic pathway served by NF- B2 and the down-
stream target genes that it regulates in these cells.
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